logo
Our Products
About Us
Contact Us
Hello Sign In
Your Account
View My
Cart

Oxynox Supplement Facts

Learn more about the ingredients in Oxynox.
Pin it
 

 

 Oxynox Supplement Facts

 Serving Size: 4 Capsules
 Servings Per Container:  30



  Amount
Per Serving
Daily Value


 Vitamin C (Ascorbic Acid)

1000 mg 1666%

 Vitamin A (Acetate)

15000 IU 300%

 Magnesium (Oxide) 250 mg 63%




 N-Acetyl Cysteine

600 mg *

 Alpha Lipoic Acid

100 mg *

 Mullein Leaf Extract (Verbascum thapsus)

250 mg *

 Elecampane Extract (Inula helenium) (root) 125 mg *


 *Daily Value Not Established



Daily Dosage: As a dietary supplement, take one capsule in the morning and one capsule in the afternoon with 8 ounces of water. 45-60 days of continuous use is necessary for optimum results.

 

Oxynox Research:

N-acetyl-cysteine (NAC)- NAC is the most promising natural and conventional therapy for emphysema and COPD (chronic obstructive pulmonary disease) patients, acting as a mucolytic agent, antioxidant and anti-inflammatory (1).

A clinical trial of oral NAC given to COPD patients for two months showed a significant reduction in oxidative stress (2). Rats exposed to environmental cigarette smoke that were given NAC experienced reduced molecular changes associated with development of emphysema and other smoke related illnesses (3). Functional changes (like expiratory flow) of induced emphysema in animals are also attenuated by oral NAC administration (4).


Vitamin C- As an antioxidant, vitamin C may be an effective preventative agent for COPD and emphysema. Adults who consume more fruits high in vitamin C display improved forced expiratory volume (FEV1), a measure of lung capacity (6).

Vitamin C supplementation can protect against white blood cell adhesion and aggregation (caused by smoke exposure) that is seen in emphysema (5). A recent study concluded that antioxidant status (including vitamin C) can contribute to chronic airflow limitations, like those seen in emphysema (7). One study indicated that low antioxidant levels, like plasma vitamin C, may act independently of cigarette smoke in the pathogenesis of emphysema (8).


Vitamin A- Another antioxidant vitamin important in patients with COPD and emphysema, vitamin A levels (and vitamin E) are reduced during exacerbations suggesting administration of both nutrients can be helpful in preventing and treating these diseases (9). Research shows that low vitamin A status is correlated with poor emphysema outcomes and vitamin A may improve lung function (10).

Animal studies show that retinoic acid (a form of vitamin A) plays a role in regeneration of alveoli (small air sacs in the lung) and may be a useful treatment approach (11). As well, smoking causes depletion of vitamin A which can lead to development of emphysema (12). Patients with emphysema given all-trans retinoic acid demonstrate positive changes in proteins associated with disease progression (13).


Magnesium- An essential mineral, magnesium works to relax constricted bronchial muscles in the lungs and is a more effective treatment for acute exacerbations of COPD when combined with a beta-agonist drug than the drug alone (14). Patients with COPD who have low levels of magnesium are at increased risk of exacerbations, displaying increased airway hyperactivity and impaired pulmonary function (15).

Lipoic acid- A powerful free radical scavenger (or antioxidant), lipoic acid assists in the regeneration of other antioxidants in lung tissue (16). High activity of elastase (an enzyme in the lung) causes damage in emphysema, which can be reduced with lipoic acid (17).


Mullein (Verbascum thapsus)- Traditionally used as a mucolytic for treating lung diseases, mullein has demonstrated antibacterial activity against Klebsiella pneumonia, Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli (18).


Elecampane (Inula helenium)- Also used historically as a mucolytic agent, elecampane may be useful for patients with emphysema and COPD. Research shows that an extract of elecampane can correct stress induced by hypoxia (low levels of oxygen) and contains beneficial antioxidant compounds (19,20).

References:

1. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review. Pulm Pharmacol Ther 2006 Feb 1;

2. De Benedetto F et al. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005;18(1):41-7. Epub 2004 Dec 8.

3. Izzotti A et al. Chemoprevention of genome, transcriptome, and proteome alterations induced by cigarette smoke in rat lung. Eur J Cancer 2005 Sep;41(13):1864-74.

4. Rubio ML et al. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004 Apr;125(4):1500-6.

5. Lehr HA, Frei B, Arfors KE. Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. Proc Natl Acad Sci USA 1994 Aug 2;91(16):7688-92.

6. Strachan DP et al. Ventilatory function and winter fresh fruit consumption in a random sample of British adults. Thorax 1991 Sep;46(9):624-9.

7. Ochs-Balcom HM et al. Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. Eur J Clin Nutr 2006 Feb 15;

8. Calikoglu M et al. The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers. Clin Chem Lab Med 2002 Oct;40(10):1028-31.

9. Tug T, Karatas F, Terzi SM. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2004 Jun;27(3):123-8.

10. Paiva SA et al. Assessment of vitamin A status in chronic obstructive pulmonary disease patients and healthy smokers. Am. J. Clin. Nutr. 1996 Dec; 64(6): 928-34.

11. Maden M, Hind M. Retinoic acid in alveolar development, maintenance and regeneration. Philos Trans R Soc Lond B Biol Sci 2004 May 29;359(1445):799-808.

12. Li T et al. Vitamin A depletion induced by cigarette smoke is associated with the development of emphysema in rats. J Nutr 2003 Aug;133(8):2629-34.

13. Mao JT et al. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003 Nov;124(5):1724-32.

14. Skorodin MS et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 1995;155:496-500.

15. Aziz HS et al. Serum magnesium levels and acute exacerbation of chronic obstructive pulmonary disease: a retrospective study. Ann Clin Lab Sci 2005 Autumn;35(4):423-7.

16. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997;29:315-31.

17. Biewenga G, de Jong J, Bast A. Lipoic acid favors thiolsulfinate formation after hypochlorous acid scavenging: a study with lipoic acid derivatives. Arch Biochem Biophys 1994 Jul;312(1):114-20.

18. Turker AU, Camper ND. Biological activity of common mullein, a medicinal plant. J Ethnopharmacol 2002 Oct;82(2-3):117-25.

19. Zelenskaya KL et al. Stress-inducing effect of hypoxia of different origin and its correction with Inula Helenium L. tincture. Bull Exp Biol Med 2005 Apr;139(4):414-7.

20. Kogure K et al. Novel antioxidants isolated from plants of the genera Ferula, Inula, Prangos and Rheum collected in Uzbekistan. Phytomedicine 2004 Nov;11(7-8):645-51.


FEATURED PRODUCT